Tolevamer for clostridium difficile associate diarrhoea
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 June 2007
Topic area
  • Digestive system

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Assessment Group / Evidence Review Group: TBC
Communications manager: TBC
Executive Lead: Gillian Leng
Project manager: TBC


Key events during the development of the guidance:

Date Update
14 May 2014

As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of tolevamer for clostridium difficile..

Following an update on the regulatory status of this technology, the manufacturer has informed us that development on tolevamer for clostridium difficile has stopped and there are no plans to seek regulatory approval. Therefore, the appraisal remains suspended.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual